| Year |
Citation |
Score |
| 2021 |
Guo X, Kazanova A, Thurmond S, Saragovi HU, Rudd CE. Effective chimeric antigen receptor T cells against SARS-CoV-2. Iscience. 24: 103295. PMID 34693218 DOI: 10.1016/j.isci.2021.103295 |
0.32 |
|
| 2021 |
Brahimi F, Galan A, Siegel S, Szobota S, Sarumic MV, Foster AC, Saragovi HU. . Molecular Pharmacology. PMID 34470776 DOI: 10.1124/molpharm.121.000301 |
0.476 |
|
| 2020 |
Brahimi F, Galan A, Jmaeff S, Barcelona PF, De Jay N, Dejgaard K, Young JC, Kleinman CL, Thomas DY, Saragovi HU. Alternative Splicing of a Receptor Intracellular Domain Yields Different Ectodomain Conformations, Enabling Isoform-Selective Functional Ligands. Iscience. 23: 101447. PMID 32829283 DOI: 10.1016/J.Isci.2020.101447 |
0.354 |
|
| 2020 |
Mossa AH, Galan A, Cammisotto PG, Velasquez Flores M, Shamout S, Barcelona P, Saragovi HU, Campeau L. Antagonism of proNGF or its receptor p75 reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia. PMID 32699962 DOI: 10.1007/S00125-020-05222-4 |
0.328 |
|
| 2020 |
Jmaeff S, Sidorova Y, Lippiatt H, Barcelona PF, Nedev H, Saragovi LM, Hancock MA, Saarma M, Saragovi HU. Small-molecule ligands that bind the RET receptor activate neuroprotective signals independent of but modulated by co-receptor GFRα1. Molecular Pharmacology. PMID 32362584 DOI: 10.1124/Mol.119.118950 |
0.412 |
|
| 2020 |
Jmaeff S, Sidorova Y, Nedev H, Saarma M, Saragovi HU. Small-molecule agonists of the RET receptor tyrosine kinase activate biased trophic signals that are influenced by the presence of GFRa1 co-receptors. The Journal of Biological Chemistry. 295: 6532-6542. PMID 32245892 DOI: 10.1074/Jbc.Ra119.011802 |
0.335 |
|
| 2019 |
Saragovi HU, Galan A, Levin LA. Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration. Frontiers in Cellular Neuroscience. 13: 231. PMID 31244606 DOI: 10.3389/fncel.2019.00231 |
0.389 |
|
| 2016 |
Josephy-Hernandez S, Jmaeff S, Pirvulescu I, Aboulkassim T, Saragovi HU. Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm. Neurobiology of Disease. 97: 139-155. PMID 27546056 DOI: 10.1016/J.Nbd.2016.08.004 |
0.331 |
|
| 2015 |
Tong W, Maira M, Gagnon M, Saragovi HU. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. Plos One. 10: e0134255. PMID 26252487 DOI: 10.1371/journal.pone.0134255 |
0.364 |
|
| 2015 |
Barcelona PF, Saragovi HU. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Molecular and Cellular Biology. 35: 3396-408. PMID 26217017 DOI: 10.1128/Mcb.00544-15 |
0.435 |
|
| 2015 |
Goupil E, Fillion D, Clément S, Luo X, Devost D, Sleno R, Pétrin D, Saragovi HU, Thorin É, Laporte SA, Hébert TE. Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells. The Journal of Biological Chemistry. 290: 3137-48. PMID 25512374 DOI: 10.1074/Jbc.M114.631119 |
0.338 |
|
| 2014 |
Brahimi F, Ko E, Malakhov A, Burgess K, Saragovi HU. Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors Plos One. 9. PMID 24603864 DOI: 10.1371/Journal.Pone.0089617 |
0.376 |
|
| 2012 |
Ettinger K, Lecht S, Arien-Zakay H, Cohen G, Aga-Mizrachi S, Yanay N, Saragovi HU, Nedev H, Marcinkiewicz C, Nevo Y, Lazarovici P. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cellular Signalling. 24: 2378-88. PMID 22960610 DOI: 10.1016/J.Cellsig.2012.08.008 |
0.328 |
|
| 2010 |
Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC, ZhiHua S, Mehta HM, Woo SB, Sarunic MV, Neet KE, Saragovi HU. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. The Journal of Biological Chemistry. 285: 39392-400. PMID 20943663 DOI: 10.1074/Jbc.M110.147801 |
0.4 |
|
| 2010 |
Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima EO, Ivanisevic L, Caron A, Burgess K, Saragovi HU. A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochimica Et Biophysica Acta. 1800: 1018-26. PMID 20600627 DOI: 10.1016/J.Bbagen.2010.06.007 |
0.401 |
|
| 2010 |
Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hébert TE, et al. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. The Journal of Biological Chemistry. 285: 25624-36. PMID 20551320 DOI: 10.1074/Jbc.M110.115196 |
0.312 |
|
| 2010 |
Liu J, Brahimi F, Saragovi HU, Burgess K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists. Journal of Medicinal Chemistry. 53: 5044-8. PMID 20540510 DOI: 10.1021/Jm100148D |
0.33 |
|
| 2010 |
Guillemard V, Ivanisevic L, Garcia AG, Scholten V, Lazo OM, Bronfman FC, Saragovi HU. An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors. Developmental Neurobiology. 70: 150-64. PMID 19953569 DOI: 10.1002/Dneu.20776 |
0.378 |
|
| 2010 |
Bassili M, Birman E, Schor NF, Saragovi HU. Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology. 65: 1047-56. PMID 19701634 DOI: 10.1007/S00280-009-1110-X |
0.597 |
|
| 2009 |
Chen D, Brahimi F, Angell Y, Li YC, Moscowicz J, Saragovi HU, Burgess K. Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. Acs Chemical Biology. 4: 769-81. PMID 19735123 DOI: 10.1021/Cb9001415 |
0.366 |
|
| 2009 |
Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides. 30: 1833-9. PMID 19647025 DOI: 10.1016/J.Peptides.2009.07.015 |
0.416 |
|
| 2009 |
Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F, Hardy P, Joyal JS, Nedev H, Duhamel F, ... ... Saragovi HU, et al. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 297: R1009-18. PMID 19641130 DOI: 10.1152/ajpregu.90766.2008 |
0.348 |
|
| 2009 |
Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Molecular and Cellular Neurosciences. 40: 410-20. PMID 19146958 DOI: 10.1016/J.Mcn.2008.12.005 |
0.43 |
|
| 2008 |
Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU, Nabi IR. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. Plos One. 3: e3597. PMID 18974847 DOI: 10.1371/Journal.Pone.0003597 |
0.374 |
|
| 2007 |
Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Developmental Neurobiology. 67: 884-94. PMID 17506493 DOI: 10.1002/Dneu.20360 |
0.44 |
|
| 2006 |
Peleshok J, Saragovi HU. Functional mimetics of neurotrophins and their receptors. Biochemical Society Transactions. 34: 612-7. PMID 16856874 DOI: 10.1042/BST0340612 |
0.403 |
|
| 2006 |
Esteban PF, Yoon HY, Becker J, Dorsey SG, Caprari P, Palko ME, Coppola V, Saragovi HU, Randazzo PA, Tessarollo L. A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. The Journal of Cell Biology. 173: 291-9. PMID 16636148 DOI: 10.1083/Jcb.200512013 |
0.401 |
|
| 2006 |
Ivanisevic L, Saragovi HU. The Neurotrophins Handbook of Biologically Active Peptides. 1407-1413. DOI: 10.1016/B978-012369442-3/50199-9 |
0.409 |
|
| 2005 |
Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, Bengio Y, Burgess K, Saragovi HU. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chemistry & Biology. 12: 1015-28. PMID 16183026 DOI: 10.1016/J.Chembiol.2005.06.015 |
0.392 |
|
| 2005 |
Tyurina YY, Nylander KD, Mirnics ZK, Portugal C, Yan C, Zaccaro C, Saragovi HU, Kagan VE, Schor NF. The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell. 4: 187-96. PMID 16026333 DOI: 10.1111/J.1474-9726.2005.00160.X |
0.576 |
|
| 2005 |
Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, Sisodia SS, Mirnics K, Schor NF. P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of Disease. 20: 969-85. PMID 16006137 DOI: 10.1016/J.Nbd.2005.06.004 |
0.593 |
|
| 2005 |
Yan C, Mirnics ZK, Portugal CF, Liang Y, Nylander KD, Rudzinski M, Zaccaro C, Saragovi HU, Schor NF. Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells. Brain Research. Molecular Brain Research. 139: 225-34. PMID 15967538 DOI: 10.1016/J.Molbrainres.2005.05.025 |
0.561 |
|
| 2005 |
Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. Dna and Cell Biology. 24: 350-8. PMID 15941387 DOI: 10.1089/Dna.2005.24.351 |
0.375 |
|
| 2005 |
Li S, Saragovi HU, Nedev H, Zhao C, Racine RJ, Fahnestock M. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Molecular and Cellular Neurosciences. 29: 162-72. PMID 15911341 DOI: 10.1016/J.Mcn.2005.02.007 |
0.371 |
|
| 2004 |
Guillemard V, Saragovi HU. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity Oncogene. 23: 3613-3621. PMID 15034547 DOI: 10.1038/Sj.Onc.1207463 |
0.324 |
|
| 2004 |
Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. Journal of Neurobiology. 58: 341-54. PMID 14750147 DOI: 10.1002/Neu.10293 |
0.404 |
|
| 2003 |
Ivanisevic L, Banerjee K, Saragovi HU. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene. 22: 5677-85. PMID 12944916 DOI: 10.1038/Sj.Onc.1206864 |
0.526 |
|
| 2002 |
Yan C, Liang Y, Nylander KD, Wong J, Rudavsky RM, Saragovi HU, Schor NF. p75-nerve growth factor as an antiapoptotic complex: independence versus cooperativity in protection from enediyne chemotherapeutic agents. Molecular Pharmacology. 61: 710-9. PMID 11901208 DOI: 10.1124/Mol.61.4.710 |
0.601 |
|
| 2001 |
Zaccaro MC, Ivanisevic L, Perez P, Meakin SO, Saragovi HU. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. The Journal of Biological Chemistry. 276: 31023-9. PMID 11425862 DOI: 10.1074/Jbc.M104630200 |
0.402 |
|
| 2000 |
la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G. Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. Journal of Leukocyte Biology. 68: 104-10. PMID 10914496 DOI: 10.1189/Jlb.68.1.104 |
0.41 |
|
| 2000 |
Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. The Journal of Biological Chemistry. 275: 9946-56. PMID 10744669 DOI: 10.1074/Jbc.275.14.9946 |
0.446 |
|
| 2000 |
Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends in Pharmacological Sciences. 21: 93-8. PMID 10689362 DOI: 10.1016/S0165-6147(99)01444-3 |
0.338 |
|
| 2000 |
Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, Saragovi HU. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Molecular Pharmacology. 57: 385-91. PMID 10648649 |
0.402 |
|
| 1999 |
Saragovi HU, Rebai N, Di Guglielmo GM, Macleod R, Sheng J, Rubin DH, Greene MI. A G1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of p21ras and mitogen-activated protein kinase. Dna and Cell Biology. 18: 763-70. PMID 10541435 DOI: 10.1089/104454999314908 |
0.414 |
|
| 1999 |
Saragovi HU, Burgess K. Small molecule and protein-based neurotrophic ligands: Agonists and antagonists as therapeutic agents Expert Opinion On Therapeutic Patents. 9: 737-751. DOI: 10.1517/13543776.9.6.737 |
0.368 |
|
| 1998 |
Saragovi HU, Zheng W, Maliartchouk S, DiGugliemo GM, Mawal YR, Kamen A, Woo SB, Cuello AC, Debeir T, Neet KE. A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. The Journal of Biological Chemistry. 273: 34933-40. PMID 9857023 DOI: 10.1074/Jbc.273.52.34933 |
0.321 |
|
| 1998 |
Roux E, Robaire B, Saragovi HU. A cell cycle regulating receptor is localized on cell surface and in nuclei of mitotically and meiotically dividing cells. Dna and Cell Biology. 17: 239-47. PMID 9539104 |
0.505 |
|
| 1997 |
Maliartchouk S, Saragovi HU. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6031-7. PMID 9236214 DOI: 10.1523/Jneurosci.17-16-06031.1997 |
0.481 |
|
| 1996 |
LeSauteur L, Cheung NK, Lisbona R, Saragovi HU. Small molecule nerve growth factor analogs image receptors in vivo. Nature Biotechnology. 14: 1120-2. PMID 9631063 DOI: 10.1038/nbt0996-1120 |
0.371 |
|
| 1996 |
LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 1308-16. PMID 8778282 DOI: 10.1523/Jneurosci.16-04-01308.1996 |
0.375 |
|
| 1996 |
Rebai N, Almazan G, Wei L, Greene MI, Saragovi HU. A p65/p95 neural surface receptor is expressed at the S-G2 phase of the cell cycle and defines distinct populations. The European Journal of Neuroscience. 8: 273-81. PMID 8714698 DOI: 10.1111/J.1460-9568.1996.Tb01211.X |
0.523 |
|
| 1995 |
LeSauteur L, Wei L, Gibbs BF, Saragovi HU. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. The Journal of Biological Chemistry. 270: 6564-9. PMID 7896793 DOI: 10.1074/Jbc.270.12.6564 |
0.357 |
|
| 1995 |
Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. The Journal of Clinical Investigation. 95: 1814-23. PMID 7706488 DOI: 10.1172/JCI117860 |
0.346 |
|
| 1995 |
Saragovi HU, Bhandoola A, Lemercier MM, Akbar GK, Greene MI. A receptor that subserves reovirus binding can inhibit lymphocyte proliferation triggered by mitogenic signals. Dna and Cell Biology. 14: 653-64. PMID 7646812 DOI: 10.1089/Dna.1995.14.653 |
0.452 |
|
| 1993 |
Sauvé GJ, Saragovi HU, Greene MI. Reovirus receptors. Advances in Virus Research. 42: 325-41. PMID 8430522 |
0.363 |
|
| Show low-probability matches. |